Early clinical studies support their feasibility, as shown by FT596, an iPSC-derived CAR-NK engineered with IL-15 support, which demonstrated antitumor activity and a favorable safety profile in CD19+ lymphoma (Kim, 2025). This evidence concerns the gene CD19 and lymphoma.